Key highlights ·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia ·      Allows for use in combination with an antiviral agent ·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline   8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’),  a leading infectious disease focused biopharmaceutical company, announces that […]